Cover Page
Cover Page - shares | 9 Months Ended | |
Sep. 30, 2022 | Nov. 11, 2022 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Sep. 30, 2022 | |
Document Transition Report | false | |
Entity File Number | 000-56364 | |
Entity Registrant Name | Charlotte's Web Holdings, Inc. | |
Entity Incorporation, State or Country Code | A1 | |
Entity Tax Identification Number | 98-1508633 | |
Entity Address, Address Line One | 700 Tech Court | |
Entity Address, City or Town | Louisville | |
Entity Address, State or Province | CO | |
Entity Address, Postal Zip Code | 80027 | |
City Area Code | 720 | |
Local Phone Number | 617-7303 | |
Title of 12(g) Security | Common stock, no par value | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 151,628,652 | |
Amendment Flag | false | |
Entity Central Index Key | 0001750155 | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2022 | |
Document Fiscal Period Focus | Q3 |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Current assets: | ||
Cash and cash equivalents | $ 16,513 | $ 19,494 |
Accounts receivable, net | 2,044 | 4,882 |
Notes receivable - current | 495 | 495 |
Inventories, net | 50,599 | 52,077 |
Prepaid expenses and other current assets | 4,530 | 8,095 |
Income taxes receivable | 0 | 10,764 |
Total current assets | 74,181 | 95,807 |
Property and equipment, net | 31,087 | 36,085 |
Operating lease right-of-use assets, net | 17,079 | 20,679 |
Intangible assets, net | 2,018 | 2,843 |
Stanley Brothers USA Holdings purchase option | 9,100 | 13,000 |
Notes receivable - noncurrent | 1,037 | 1,037 |
Other long-term assets | 6,016 | 2,062 |
Total assets | 140,518 | 171,513 |
Current liabilities: | ||
Accounts payable | 2,584 | 5,049 |
Accrued and other current liabilities | 7,435 | 9,570 |
Cultivation liabilities – current | 812 | 3,448 |
Lease obligations – current | 2,316 | 2,103 |
Total current liabilities | 13,147 | 20,170 |
Cultivation liabilities – noncurrent | 0 | 385 |
Lease obligations – noncurrent | 18,507 | 20,500 |
Other long-term liabilities | 2 | 12 |
Total liabilities | 31,656 | 41,067 |
Commitments and contingencies (note 6) | ||
Shareholders’ equity: | ||
Common shares, nil par value; unlimited shares authorized as of September 30, 2022 and December 31, 2021, respectively; 145,509,372 and 144,659,964 shares issued and outstanding as of September 30, 2022 and December 31, 2021 | 1 | 1 |
Proportionate voting shares, nil par value; nil shares authorized as of September 30, 2022 and December 31, 2021, respectively; nil shares issued and outstanding as of September 30, 2022 and December 31, 2021 | 0 | 0 |
Additional paid-in capital | 321,559 | 319,059 |
Accumulated deficit | (212,698) | (188,614) |
Total shareholders’ equity | 108,862 | 130,446 |
Total liabilities and shareholders’ equity | $ 140,518 | $ 171,513 |
CONDENSED CONSOLIDATED BALANC_2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - shares | Sep. 30, 2022 | Dec. 31, 2021 | Nov. 03, 2021 |
Statement of Financial Position [Abstract] | |||
Common shares, issued (in shares) | 145,509,372 | 144,659,964 | 142,335,464 |
Common shares, outstanding (in shares) | 145,509,372 | 144,659,964 | 142,335,464 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Income Statement [Abstract] | ||||
Revenue | $ 17,037 | $ 23,704 | $ 55,271 | $ 71,263 |
Cost of goods sold | 8,092 | 8,789 | 25,291 | 26,884 |
Gross profit | 8,945 | 14,915 | 29,980 | 44,379 |
Selling, general and administrative expenses | 11,032 | 24,299 | 48,646 | 73,263 |
Asset impairment | 1,822 | 0 | 1,822 | 0 |
Operating loss | (3,909) | (9,384) | (20,488) | (28,884) |
Other income, net | 321 | 110 | 304 | 320 |
Change in fair value of financial instruments and other | (4,000) | 8,459 | (3,900) | 9,082 |
Loss before provision for income taxes | (7,588) | (815) | (24,084) | (19,482) |
Income tax benefit | 0 | 38 | 0 | 8 |
Net loss | $ (7,588) | $ (777) | $ (24,084) | $ (19,474) |
Net loss per common share, basic (in usd per share) | $ (0.05) | $ (0.01) | $ (0.17) | $ (0.14) |
Net loss per common share, diluted (in usd per share) | $ (0.05) | $ (0.01) | $ (0.17) | $ (0.14) |
Weighted-average shares used in computing net loss per share, basic (in shares) | 145,334,992 | 140,521,244 | 145,203,515 | 140,054,738 |
Weighted-average shares used in computing net loss per share, diluted (in shares) | 145,334,992 | 140,521,244 | 145,203,515 | 140,054,738 |
CONDENSED CONSOLIDATED STATEM_2
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY - USD ($) $ in Thousands | Total | Restricted share units | Proportionate Voting Shares | Common Shares | Common Shares Restricted share units | Additional Paid-in Capital | Additional Paid-in Capital Restricted share units | Accumulated Deficit |
Balance (in shares) at Dec. 31, 2020 | 81,177 | 107,060,237 | ||||||
Balance at Dec. 31, 2020 | $ 254,242 | $ 1 | $ 305,133 | $ (50,892) | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Exercise of stock options (in shares) | 8,261 | |||||||
Exercise of stock options | 30 | 30 | ||||||
Conversion to common shares (in shares) | (3,961) | 1,584,410 | ||||||
Common shares issued upon vesting of restricted share units, net of withholding (in shares) | 61,548 | |||||||
Common shares issued upon vesting of restricted share units, net of withholding | (112) | (112) | ||||||
Exercise of common stock warrants (in shares) | 98,788 | |||||||
Exercise of common stock warrants | 441 | 441 | ||||||
Harmony Hemp contingent equity compensation (in shares) | 169,046 | |||||||
Harmony Hemp contingent equity compensation | 360 | 360 | ||||||
Share-based compensation | 832 | 832 | ||||||
Net loss | (12,774) | (12,774) | ||||||
Balance (in shares) at Mar. 31, 2021 | 77,216 | 108,982,290 | ||||||
Balance at Mar. 31, 2021 | 243,019 | $ 1 | 306,684 | (63,666) | ||||
Balance (in shares) at Dec. 31, 2020 | 81,177 | 107,060,237 | ||||||
Balance at Dec. 31, 2020 | 254,242 | $ 1 | 305,133 | (50,892) | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Net loss | (19,474) | |||||||
Balance (in shares) at Sep. 30, 2021 | 37,214 | 126,290,058 | ||||||
Balance at Sep. 30, 2021 | 241,981 | $ 1 | 312,346 | (70,366) | ||||
Balance (in shares) at Mar. 31, 2021 | 77,216 | 108,982,290 | ||||||
Balance at Mar. 31, 2021 | 243,019 | $ 1 | 306,684 | (63,666) | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Conversion to common shares (in shares) | (1,327) | 530,900 | ||||||
Common shares issued upon vesting of restricted share units, net of withholding (in shares) | 16,559 | |||||||
Common shares issued upon vesting of restricted share units, net of withholding | (26) | (26) | ||||||
Harmony Hemp contingent equity compensation | 363 | 363 | ||||||
ATM program issuance costs (in shares) | 278,200 | |||||||
ATM program issuance costs | 839 | 839 | ||||||
Share-based compensation | 994 | 994 | ||||||
Net loss | (5,923) | (5,923) | ||||||
Balance (in shares) at Jun. 30, 2021 | 75,889 | 109,807,949 | ||||||
Balance at Jun. 30, 2021 | 239,266 | $ 1 | 308,854 | (69,589) | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Conversion to common shares (in shares) | (38,675) | 15,469,990 | ||||||
Common shares issued upon vesting of restricted share units, net of withholding (in shares) | 103,074 | |||||||
Common shares issued upon vesting of restricted share units, net of withholding | (5) | (5) | ||||||
Harmony Hemp contingent equity compensation (in shares) | 169,045 | |||||||
Harmony Hemp contingent equity compensation | 196 | 196 | ||||||
ATM program issuance costs (in shares) | 740,000 | |||||||
ATM program issuance costs | 1,918 | 1,918 | ||||||
Share-based compensation | 1,383 | 1,383 | ||||||
Net loss | (777) | (777) | ||||||
Balance (in shares) at Sep. 30, 2021 | 37,214 | 126,290,058 | ||||||
Balance at Sep. 30, 2021 | 241,981 | $ 1 | 312,346 | (70,366) | ||||
Balance (in shares) at Dec. 31, 2021 | 0 | 144,659,964 | ||||||
Balance at Dec. 31, 2021 | 130,446 | $ 1 | 319,059 | (188,614) | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Common shares issued upon vesting of restricted share units, net of withholding (in shares) | 77,193 | |||||||
Common shares issued upon vesting of restricted share units, net of withholding | $ (45) | $ (45) | ||||||
Harmony Hemp contingent equity compensation (in shares) | 169,045 | |||||||
Harmony Hemp contingent equity compensation | 165 | 165 | ||||||
ATM program issuance costs (in shares) | 239,500 | |||||||
ATM program issuance costs | (2) | (2) | ||||||
Share-based compensation | 1,214 | 1,214 | ||||||
Net loss | (8,626) | (8,626) | ||||||
Balance (in shares) at Mar. 31, 2022 | 0 | 145,145,702 | ||||||
Balance at Mar. 31, 2022 | 123,152 | $ 1 | 320,391 | (197,240) | ||||
Balance (in shares) at Dec. 31, 2021 | 0 | 144,659,964 | ||||||
Balance at Dec. 31, 2021 | $ 130,446 | $ 1 | 319,059 | (188,614) | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Exercise of stock options (in shares) | 0 | |||||||
Net loss | $ (24,084) | |||||||
Balance (in shares) at Sep. 30, 2022 | 0 | 145,509,372 | ||||||
Balance at Sep. 30, 2022 | 108,862 | $ 1 | 321,559 | (212,698) | ||||
Balance (in shares) at Mar. 31, 2022 | 0 | 145,145,702 | ||||||
Balance at Mar. 31, 2022 | 123,152 | $ 1 | 320,391 | (197,240) | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Common shares issued upon vesting of restricted share units, net of withholding (in shares) | 132,463 | |||||||
Common shares issued upon vesting of restricted share units, net of withholding | (13) | (13) | ||||||
Share-based compensation | 643 | 643 | ||||||
Net loss | (7,870) | (7,870) | ||||||
Balance (in shares) at Jun. 30, 2022 | 0 | 145,278,165 | ||||||
Balance at Jun. 30, 2022 | 115,912 | $ 1 | 321,021 | (205,110) | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Common shares issued upon vesting of restricted share units, net of withholding (in shares) | 231,207 | |||||||
Common shares issued upon vesting of restricted share units, net of withholding | $ (67) | $ (67) | ||||||
ATM program issuance costs | (59) | (59) | ||||||
Share-based compensation | 664 | 664 | ||||||
Net loss | (7,588) | (7,588) | ||||||
Balance (in shares) at Sep. 30, 2022 | 0 | 145,509,372 | ||||||
Balance at Sep. 30, 2022 | $ 108,862 | $ 1 | $ 321,559 | $ (212,698) |
CONDENSED CONSOLIDATED STATEM_3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | |
Cash flows from operating activities: | ||
Net loss | $ (24,084) | $ (19,474) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 5,762 | 8,228 |
Asset impairment | 1,822 | 0 |
Change in fair value of financial instruments | 3,900 | (9,082) |
Allowance for credit losses | (89) | 590 |
Inventory provision | 1,857 | 178 |
Share-based compensation | 2,686 | 4,128 |
(Gain)/Loss on disposal of assets | (97) | 267 |
Cultivation settlement reduction | (582) | 0 |
Changes in right-of-use assets | 1,877 | 0 |
Changes in operating assets and liabilities: | ||
Accounts receivable, net | 2,928 | (226) |
Inventories, net | 112 | (876) |
Prepaid expenses and other current assets | 3,086 | 112 |
Operating lease obligations | (1,665) | (81) |
Accounts payable, accrued and other liabilities | (4,238) | (439) |
Income taxes receivable | 10,764 | 523 |
Cultivation liabilities | (2,471) | (7,166) |
Other operating assets and liabilities, net | (4,167) | (6) |
Net cash used in operating activities | (2,599) | (23,324) |
Cash flows from investing activities: | ||
Purchases of property and equipment and intangible assets | (411) | (4,088) |
Proceeds from sale of assets | 354 | 9 |
Issuance of notes receivable, net of collections | 0 | 468 |
Investment in Stanley Brothers USA Holdings purchase option | 0 | (8,000) |
Other investing activities | 0 | 521 |
Net cash used in investing activities | (57) | (11,090) |
Cash flows from financing activities: | ||
Proceeds from sale of public offering, net of issuance costs | (61) | 2,896 |
Proceeds from stock option exercises | 0 | 30 |
Other financing activities | (264) | (246) |
Net cash (used) provided in financing activities | (325) | 2,680 |
Net decrease in cash and cash equivalents | (2,981) | (31,734) |
Cash and cash equivalents —beginning of period | 19,494 | 52,803 |
Cash and cash equivalents —end of period | 16,513 | 21,069 |
Non-cash activities: | ||
Non-cash purchases of property and equipment | $ 0 | $ (2,490) |
DESCRIPTION OF BUSINESS AND PRE
DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS | 9 Months Ended |
Sep. 30, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS | DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS Description of the Business Charlotte’s Web Holdings, Inc. together with its subsidiaries (collectively "Charlotte's Web" or the “Company”) is a publicly traded company incorporated pursuant to the laws of the Province of British Columbia and a Certified B Corp. The Company’s common shares are publicly listed on the Toronto Stock Exchange (“TSX”) under the symbol “CWEB” and quoted on the OTCQX under the symbol "CWBHF." The Company’s corporate headquarters is located in Louisville, Colorado in the United States of America. The majority of the Company's business is conducted in the United States of America. The Company’s primary products are made from proprietary strains of whole-plant hemp extracts containing a full spectrum of phytocannabinoids, terpenes, flavonoids and other hemp compounds. Hemp extracts are produced from the plant Cannabis sativa L. (“Cannabis”), and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol ("THC") concentration of not more than 0.3% on a dry weight basis ("Hemp"). The Company is engaged in research involving the effectiveness of a broad variety of compounds derived from Hemp. The Company’s current product categories include human ingestible products: tinctures (liquid product), capsules, gummies, sprays, topicals, and pet products. The Company’s products are distributed through its e-commerce website, third-party e-commerce websites, select distributors, health practitioners, and a variety of brick-and-mortar specialty retailers. The Company does not currently produce or sell medicinal or recreational marijuana or products derived from high-THC cannabis plants. On March 2, 2021, Charlotte’s Web executed an Option Purchase Agreement (the "SBH Purchase Option") pursuant to which the Company has the option to acquire Stanley Brothers USA Holdings, Inc. (“Stanley Brothers USA”), a cannabis wellness incubator. Until the SBH Purchase Option is exercised, both Charlotte’s Web and Stanley Brothers USA will continue to operate as standalone entities in the US. Internationally, the companies are able to explore opportunities where Cannabis is federally permissible. The Company does not currently have any plans to expand into high-THC products in the near future. The Company grows its proprietary Hemp domestically in the United States on farms leased in northeastern Colorado. Additionally, Hemp is sourced through contract farming operations in Kentucky, Oregon, and Canada. The Hemp grown in Canada is utilized exclusively in the Canadian market and not in products sold in the United States. In furtherance of the Company’s research and development ("R&D") efforts, the Company established CW Labs, an internal division for R&D, to expand the Company’s efforts around the science of Hemp derived compounds. CW Labs is currently engaged in clinical trials addressing safe Hemp-based health solutions. CW Labs is located in Louisville, Colorado at the Company’s current good manufacturing practice ("cGMP") production and distribution facility. In November 2019, the Company announced a collaboration between CW Labs and the University at Buffalo’s Center for Integrated Global Biomedical Sciences to advance hemp cannabinoid science through a research program that provides a better understanding of the therapeutic uses and safety of cannabinoids. |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES | 9 Months Ended |
Sep. 30, 2022 | |
Accounting Policies [Abstract] | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s financial position as of September 30, 2022 and its results of operations for the three and nine months ended September 30, 2022 and 2021, cash flows for the nine months ended September 30, 2022 and 2021, and stockholders’ equity for the three and nine months ended September 30, 2022 and 2021. Operating results for the three and nine months ended September 30, 2022, are not necessarily indicative of the results that may be expected for the full year ending December 31, 2022. The unaudited interim condensed consolidated financial statements presented herein do not contain the required disclosures under GAAP for annual consolidated financial statements. Certain amounts presented in prior periods have been reclassified to conform with the current period presentation. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 24, 2022. Inventories Inventories are stated at the lower of cost or net realizable value. The Company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. The Company's inventory production process for cannabinoid products includes the cultivation of botanical raw material. Because of the duration of the cultivation process, a portion of the inventory will not be sold within one year. Consistent with the practice in other industries that cultivate botanical raw materials, all inventory is classified as a current asset. Revenue Recognition The majority of the Company’s revenue is derived from sales of branded products to consumers via the Company's direct-to-consumer e-commerce website, and distributors, retail and wholesale business-to-business customers. The following table sets forth the disaggregation of the Company’s revenue: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Direct-to-consumer $ 11,759 $ 15,175 $ 38,174 $ 46,988 Business-to-business 5,278 8,529 17,097 24,275 Total $ 17,037 $ 23,704 $ 55,271 $ 71,263 Substantially all of the Company’s revenue is earned in the United States. Recently Adopted Accounting Pronouncements Other than described below, no new accounting pronouncements adopted or issued by the FASB had or may have a material impact on the Company’s condensed consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which aims to reduce complexity in accounting standards by improving certain areas of U.S. GAAP without compromising information provided to users of financial statements. ASU 2019-12 is effective for public entities for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. For all other entities, the standard is effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted. There was an immaterial impact upon adoption on the condensed consolidated financial statements. In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance , which addresses that Current GAAP has no specific authoritative guidance on the accounting for, or the disclosure of, government assistance received by business entities. The pronouncement and subsequent amendments require the following annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy: 1) Information about the nature of the transactions and the related accounting policy used to account for the transactions; 2) The line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item, 3) Significant terms and conditions of the transactions, including commitments and contingencies. ASU 2021-10 is effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The Company evaluated the impact of the pronouncement, see further discussion within the Notes to Condensed Consolidated Financial Statements section "Income and Other Taxes". Recently Issued Accounting Pronouncements In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2020-04, Reference Rate Reform (Topic 848)—Facilitation of the Effects of Reference Rate Reform on Financial Reporting . This standard provides optional guidance for a limited time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments in this standard apply only to contracts and hedging relationships that reference LIBOR or another reference rate expected to be discontinued due to reference rate reform. The expedients and exceptions provided by the amendments do not apply to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022. The Company is currently evaluating the impact, if any, that the updated standard will have on the condensed consolidated financial statements. In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40):Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for convertible instruments by removing the separation 8 models for convertible debt instruments and convertible preferred stock with (1) cash conversion features, and (2) beneficial conversion features. In addition, ASU 2020-06 enhances information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 is effective for emerging growth companies for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company will evaluate the impact of the pronouncement and determined if there is any impact to the condensed consolidated financial statements if preferred shares are issued in future periods. |
FAIR VALUE MEASUREMENT
FAIR VALUE MEASUREMENT | 9 Months Ended |
Sep. 30, 2022 | |
Fair Value Disclosures [Abstract] | |
FAIR VALUE MEASUREMENT | FAIR VALUE MEASUREMENT The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis at September 30, 2022 and December 31, 2021, by level within the fair value hierarchy: September 30, 2022 Level 1 Level 2 Level 3 Total Financial assets: Stanley Brothers USA Purchase Option $ — $ — $ 9,100 $ 9,100 December 31, 2021 Level 1 Level 2 Level 3 Total Financial assets: Stanley Brothers USA Purchase Option $ — $ — $ 13,000 $ 13,000 There were no transfers between levels of the hierarchy during the three and nine month periods ended September 30, 2022 and the year ended December 31, 2021. Stanley Brothers USA Purchase Option In 2021, the Company entered into an option purchase agreement with Stanley Brothers USA. The SBH Purchase Option was purchased for total consideration of $8,000 and has a five The Company has elected the fair value option in accordance with ASC 825-10 guidance to record its SBH Purchase Option. Under ASC 825-10, a business entity shall report unrealized gains and losses on items for which the fair value option has been elected in earnings at each subsequent reporting date. The SBH Purchase Option is classified as a financial asset and is remeasured at fair value at each reporting date, with changes to fair value recognized in the statements of operations for the period. The use of assumptions for the fair value determination includes a high degree of subjectivity and judgment using unobservable inputs (level 3 on the fair value hierarchy), which results in estimation uncertainty. Changes in assumptions that reasonably could have been different at the reporting date may result in a higher or lower determination of fair value. Changes in fair value measurements, if significant, may affect performance of cash flows. For the three and nine months ended September 30, 2022, a $4,000 and $3,900 loss, respectively, related to the SBH Purchase Option was recognized as change in fair value of financial instruments and other in the statements of operations. For the three and nine months ended September 30, 2021, a $5,730 and $4,900 gain, respectively, related to the SBH Purchase Option was recognized as change in fair value of financial instruments and other in the statements of operations. As of September 30, 2022 and December 31, 2021, the SBH Purchase Option represents a financial asset of $9,100 and $13,000, respectively, in the condensed consolidated balance sheets. The Monte Carlo valuation model considers multiple revenue and Earnings Before Interest Taxes Depreciation and Amortization ("EBITDA") outcomes for Stanley Brothers USA and other probabilities in assigning a fair value. Primary assumptions utilized include financial projections of Stanley Brothers USA and the probability and timing of exercise. The following additional assumptions are used in the model of the SBH Purchase Option: September 30, December 31, 2022 2021 Expected volatility 87.5% 92.5% Expected term (years) 2.9 3.7 Risk-free interest rate 4.2% 1.1% Weighted average cost of capital 45.0% 40% Warrant Liabilities The warrants offered during 2020 (the "2020 Share Offering Warrants") did not meet all of the criteria for equity classification as the warrants were denominated in Canadian dollars, which differs from the Company's functional currency. As a result, the 2020 Share Offering Warrants were initially measured at fair value and were revalued at each reporting period using the Black-Scholes option pricing model based on Level 2 observable inputs. The assumptions used by the Company were the quoted price of the Company’s common shares in an active market, risk-free interest rate, volatility and expected life, and assumes no dividends. Volatility was based on the actual historical market activity of the Company’s shares. The expected life was based on the remaining contractual term of the warrants and the risk-free interest rate was based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the expected life of the warrants. On June 18, 2022, the 2020 Share Offering Warrants expired, totaling 5,750,000 common shares, with a weighted average exercise price per warrant of $6.27. |
INVENTORIES
INVENTORIES | 9 Months Ended |
Sep. 30, 2022 | |
Inventory Disclosure [Abstract] | |
INVENTORIES | INVENTORIES Inventories consist of the following: September 30, December 31, 2022 2021 Harvested hemp and seeds $ 37,444 $ 38,249 Raw materials 12,617 15,189 Finished goods 14,865 13,974 64,926 67,412 Less: inventory provision (14,327) (15,335) Total inventory $ 50,599 $ 52,077 |
DEBT
DEBT | 9 Months Ended |
Sep. 30, 2022 | |
Debt Disclosure [Abstract] | |
DEBT | DEBT Line of Credit The Company terminated the asset backed line of credit ("ABL") for $10,000 with J.P. Morgan on July 27, 2022. Borrowings under the ABL bore interest at a variable rate based on (A) CB Floating Rate defined as Prime Rate plus 1.0% or (B) monthly LIBOR rate plus 2.50%. Borrowings under the ABL were secured by all of the assets of the Company and guaranteed by other subsidiaries of the Company. The line of credit agreement required compliance by the Company with certain debt covenants. As of the termination date and December 31, 2021, the Company was not in compliance with the debt covenants and had not drawn on the line of credit. |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 9 Months Ended |
Sep. 30, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | COMMITMENTS AND CONTINGENCIES Legal ContingenciesFrom time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. Although the ultimate aggregate amount of monetary liability or financial impact with respect to these matters is subject to many uncertainties and is therefore not predictable with assurance, management believes that as of September 30, 2022 there are no litigation pending that could have, individually and in the aggregate, a material adverse effect on the Company’s financial position, results of operations or cash flows. |
LEASES
LEASES | 9 Months Ended |
Sep. 30, 2022 | |
Leases [Abstract] | |
LEASES | LEASES The Company has lease arrangements related to office space, warehouse and production space, and land to facilitate agricultural operations. The leases have remaining lease terms of less than a year to 12 years, some of which include options to extend the leases for up to 5 years. Generally, the lease agreements do not include options to terminate the lease. Maturities of operating lease liabilities as of September 30, 2022 are as follows: Operating Leases Year Ending December 31: 2022 (3 months remaining) $ 867 2023 3,415 2024 3,205 2025 2,896 2026 2,172 Thereafter 15,595 Total lease obligation 28,150 Less: Imputed interest (7,327) Total lease liabilities 20,823 Less: Current lease liabilities 2,316 Total non-current lease liabilities $ 18,507 During the quarter, the Company made the decision to cease utilizing the Denver office space and plans to sublease the office space at current market rents. Based on an analysis of the estimated undiscounted cash flows relative to a potential sublease arrangement, the Company evaluated the recoverability of the assets associated with the subleased space, including, the right-of-use asset and concluded the asset was impaired. The Company recorded an impairment charge of $1,822 in the consolidated statements of operations for the three and nine months ended September 30, 2022. There were no such impairments for the three and nine months ended September 30, 2021. |
CULTIVATION LIABILITIES
CULTIVATION LIABILITIES | 9 Months Ended |
Sep. 30, 2022 | |
Cultivation Liabilities [Abstract] | |
CULTIVATION LIABILITIES | CULTIVATION LIABILITIES Future payments due under cultivation contract obligations are as follows: Short-term Long-term Total December 31, 2021 $ 3,448 $ 385 $ 3,833 Crop costs incurred 169 — 169 Payments (2,640) — (2,640) Settlement reductions (582) — (582) Interest 32 — 32 Conversion to short-term borrowings 385 (385) — September 30, 2022 $ 812 $ — $ 812 |
SHAREHOLDERS_ EQUITY
SHAREHOLDERS’ EQUITY | 9 Months Ended |
Sep. 30, 2022 | |
Equity [Abstract] | |
SHAREHOLDERS’ EQUITY | SHAREHOLDERS’ EQUITY As of September 30, 2022 and December 31, 2021, the Company’s share capital consists of one class of issued and outstanding shares: common shares. The Company is also authorized to issue preferred shares issuable in series. To date, no shares of preferred shares have been issued or are outstanding. On November 3, 2021, all outstanding proportionate voting shares ("PVS") of the Company were converted by way of mandatory conversion in accordance with the Company’s articles and at the discretion of the Company, into common shares. Following this conversion, and as of the close of business on November 3, 2021, 142,335,464 common shares were issued and outstanding, nil PVS were issued and outstanding and nil preferred shares were issued and outstanding. Pursuant to the Company’s Articles, the Company is no longer authorized to issue additional PVS. As of September 30, 2022 and December 31, 2021, the Company had no PVS issued and outstanding. Common Shares As of September 30, 2022 and December 31, 2021, the Company was authorized to issue an unlimited number of common shares, which have no par value. Preferred Shares As of September 30, 2022 and December 31, 2021, the Company was authorized to issue an unlimited number of preferred shares, which have no par value. Share Offering Warrants – Liability Classified The following summarizes the number of warrants outstanding as of September 30, 2022: Number of Warrants Weighted-Average Exercise Price per Warrant Outstanding as of December 31, 2021 6,983,140 $ 7.86 Granted — — Exercised — — Expired (6,983,140) $ 7.86 Outstanding as of September 30, 2022 — — As of September 30, 2022, there are no outstanding warrants. On May 8, 2022, warrants, pursuant to the Abacus acquisition, totaling 1,233,140, with a weighted average exercise price per warrant of $15.29 expired. In addition, on June 18, 2022, the 2020 Share Offering Warrants , totaling 5,750,000 common shares, with a weighted average exercise price per warrant of $6.27 expired. |
LOSS PER SHARE
LOSS PER SHARE | 9 Months Ended |
Sep. 30, 2022 | |
Earnings Per Share [Abstract] | |
LOSS PER SHARE | LOSS PER SHARE The Company computes loss per share of common shares and PVS under the two-class method required for multiple classes of common shares and participating securities. The rights, including the liquidation and dividend rights, of the two classes of shares are similar except for the 400:1 conversion ratio between the common shares and PVS shares. Accordingly, the loss per share attributable to common shareholders will be the same for common shares and PVS, on either an individual or combined basis. Basic net loss per common share and PVS is computed by dividing the allocated net loss by the weighted-average number of common shares outstanding and weighted average number of PVS outstanding during the period. Diluted loss per common share is computed by dividing the allocated net loss by the weighted-average number of common shares together with the number of additional common shares that would have been outstanding if all potentially dilutive common shares had been issued, unless anti-dilutive. Diluted loss per PVS is computed by dividing the allocated net loss by the weighted-average number of PVS outstanding during the period. The following table sets forth the computation of basic and dilutive net loss per share attributable to common shareholders: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Net loss $ (7,588) $ (777) $ (24,084) $ (19,474) Weighted-average number of common shares - basic 145,334,992 120,270,444 145,203,515 112,688,338 Dilutive effect of stock options and awards — — — — Weighted-average number of proportionate voting shares - basic — 50,627 — 68,416 Weighted-average number of common shares - diluted 145,334,992 120,270,444 145,203,515 112,688,338 Weighted-average number of proportionate voting shares - diluted — 50,627 — 68,416 Loss per common share – basic and diluted $ (0.05) $ (0.01) $ (0.17) $ (0.14) Loss per proportionate voting share – basic and diluted $ — $ (2.21) $ — $ (55.62) On October 12, 2022, the Company issued 6,119,121 common shares as part of the MLB Subscription Agreement. Additionally, on November 14, 2022, as part of the BAT Subscription Agreement, the Company issued 37,670,540 shares. Refer to additional disclosure within the Subsequent Events section of the Notes to Condensed Consolidated Financial Statements. As of September 30, 2022 and 2021, potentially dilutive securities include stock options, restricted share units, broker warrants, and common share warrants. When the Company recognizes a net loss, all potentially dilutive shares are anti-dilutive and are consequently excluded from the calculation of diluted net loss per share. The potentially dilutive awards outstanding for each year are presented in the table below: September 30, 2022 2021 Outstanding options 4,625,261 3,881,721 Outstanding restricted share units 2,843,470 872,311 Outstanding common share warrants — 9,483,140 Total 7,468,731 14,237,172 |
STOCK-BASED COMPENSATION
STOCK-BASED COMPENSATION | 9 Months Ended |
Sep. 30, 2022 | |
Share-Based Payment Arrangement [Abstract] | |
SHARE-BASED COMPENSATION | SHARE-BASED COMPENSATION Stock options Stock options vest over a prescribed service period and are approved by the Company's board of directors on an award-by-award basis. Options have a prescribed service period generally lasting up to four years, with certain options having a shorter vesting period or vesting immediately upon issuance. Upon the exercise of any stock options, the Company issues shares to the award holder from the pool of authorized but unissued common shares. The fair values of options granted during the period were determined using a Black-Scholes model. The following principal inputs were used in the valuation of awards issued for the nine months ended September 30, 2022 and 2021: Nine Months Ended September 30, 2022 2021 Expected volatility 85.8% 82.5% Expected term (years) 6.0 6.0 Risk-free interest rate 3.3% 1.3% Expected dividend yield 0% 0% Value of underlying share $0.43 $2.18 Detail of the number of stock options outstanding for the three months ended September 30, 2022 under the Company's 2015 legacy option plan and the Company's amended 2018 long term incentive plan (collectively, the "Plans") is as follows: Number of Options Weighted- per Option Weighted- (in years) Aggregate Outstanding as of December 31, 2021 3,343,883 $ 3.16 7.54 $ 1,039,229 Granted 3,813,579 1.11 Exercised — — Forfeited (and expired) (2,532,201) 3.32 Outstanding as of September 30, 2022 4,625,261 $ 1.41 8.78 $ 170,184 Exercisable/vested as of September 30, 2022 1,579,296 $ 1.59 6.16 $ 14,184 The weighted average grant-date fair value of options granted during the nine months ended September 30, 2022 was $1.11. The weighted average grant-date fair value of options granted during the nine months ended September 30, 2021 was $4.63. The weighted average share price at the date of exercise of options exercised during the nine months ended September 30, 2022 and 2021 was $0 and $3.64, respectively. Restricted share units The Company has issued time-based restricted share units to certain employees as permitted under the 2018 Plan. The restricted share units granted vest in accordance with the board-approved agreement, typically over equal installments over up to four years. Upon vesting, one of the Company’s common shares is issued for each restricted share unit awarded. The fair value of each restricted share unit granted is equal to the market price of the Company’s shares at the date of the grant. The fair value of shares vested during the nine months ended September 30, 2022 and September 30, 2021 was $881 and $354, respectively. Details of the number of restricted share units outstanding under the 2018 Plan is as follows: Number of Shares Weighted- Outstanding as of December 31, 2021 1,816,851 $ 2.28 Granted 3,380,777 $ 0.91 Forfeited (1,748,387) $ 1.85 Vested (440,863) $ 2.00 Shares withheld upon vesting (164,908) $ 1.58 Outstanding as of September 30, 2022 2,843,470 $ 0.99 Share-based Compensation Expense Share-based compensation expense for all equity arrangements for the three months ended September 30, 2022 and September 30, 2021 was $664 and $1,579, respectively, included in selling, general and administrative expense in the condensed consolidated statements of operations and comprehensive loss. Share-based compensation expense for all equity arrangements for the nine months ended September 30, 2022 and September 30, 2021 was $2,686 and $4,128, respectively, included in selling, general and administrative expense in the condensed consolidated statements of operations and comprehensive loss. As of September 30, 2022, $6,114 of total unrecognized share-based compensation expense related to unvested options and restricted stock units granted to employees is expected to be recognized over a weighted-average period of 2.50 years. |
INCOME AND OTHER TAXES
INCOME AND OTHER TAXES | 9 Months Ended |
Sep. 30, 2022 | |
Income Tax Disclosure [Abstract] | |
INCOME AND OTHER TAXES | INCOME AND OTHER TAXES The Company’s effective tax rate during the nine months ended September 30, 2022 and 2021 was 0%, respectively. The Company’s effective tax rates differ from the U.S. federal statutory rate of 21% for the nine months ended September 30, 2022 and 2021, respectively, primarily due to the Company being in a full valuation allowance. As of September 30, 2022 , the Company has received $10,841 from the Internal Revenue Service ("IRS") which was the remaining amount of the income taxes receivable and interest. |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 9 Months Ended |
Sep. 30, 2022 | |
Related Party Transactions [Abstract] | |
RELATED PARTY TRANSACTIONS | RELATED PARTY TRANSACTIONS Aidance Scientific, Inc. (“Aidance”) is the manufacturer of nearly all Abacus Health products. The former Chief Executive Officer of Abacus Products, Inc. ("Abacus"), and a former officer of the Company, also serves on Aidance’s Board of Directors. For the three and nine months ended September 30, 2022 and 2021, the Company made purchases of $1,254 and $947 and $2,943 and $3,133, respectively from Aidance. Payment terms on purchases are due 30 days after receipt. As of September 30, 2022, the Company had a liability of $258 due to Aidance presented in accounts payable in the condensed consolidated balance sheets. As of December 31, 2021, the Company had a liability of $119 due to Aidance presented in accounts payable in the consolidated balance sheets. Effective November 2020, the Company entered into a note receivable with certain founders of the Company ("founders") to negotiate a future binding transaction in good faith. This agreement included a secured promissory note, where $1,000 was loaned to one of the founders. The note receivable is secured by equity instruments with certain founders of the Company, is carried at amortized cost, bore interest at 3.25% per year, and required the unpaid principal and unpaid interest balances to be paid on or before the maturity date of November 13, 2021. The founders requested an extension of the maturity date, as allowed under the terms of the promissory note, resulting in an extension of the maturity date to November 13, 2023. According to the terms of the agreement, no additional interest will accrue through the payment date. The founders' equity instruments securing the promissory note remained in place. Interest income is recognized based upon the contractual interest rate and unpaid principal balance of the promissory note. As of September 30, 2022 and December 31, 2021, the founders owed the Company $1,037 consisting of principal and interest. On March 22, 2022, the Company and the founders amended the agreement to increase the equity instruments securing the promissory note and to extend the maturity date to November 13, 2023. As a result of this amendment, the Company does not believe there is an estimated credit loss on the note receivable as of September 30, 2022 and December 31, 2021. The Company will continue to evaluate the note receivable for changes to credit loss estimates through the extended maturity date. On March 2, 2021, the Company entered into the SBH Purchase Option with Stanley Brothers USA as discussed above (Note 3). The SBH Purchase Option was purchased for total consideration of $8,000. Certain founders of the Company, who are or were employees at the time, are the majority shareholders of Stanley Brothers USA. On September 30, 2022, pursuant to an amendment to the Name and Likeness and License Agreement between the Company and Leeland & Sig LLC d/b/a Stanley Brothers Brand Company, agreement was extended to December 31, 2022. The Name and Likeness Agreement was amended to provide the payment of a nominal per diem fee for each Stanley brother that participates in certain events. In addition, on April 16, 2021, the Company executed a separate consulting agreement which extended the services agreements of the seven Stanley brothers for a period of one year, expiring July 31, 2022. Upon execution of the consulting agreement in 2021, the Company paid $2,081 to Leeland & Sig LLC d/b/a Stanley Brothers Brand Company, on behalf of the seven Stanley brothers, as consideration for the consulting services to be provided to the Company over the term of the agreement and certain restrictive covenants. For the three and nine months ended September 30, 2022, the Company recognized $150 and $1,025, respectively in sales and marketing expenses in the condensed consolidated statements of operations and net loss related to this agreement. For the three and nine months ended September 30, 2021, the Company recognized $167 of selling, general and administrative expenses in the condensed consolidated statements of operations and net loss related to this agreement. As September 30, 2022 there is no remaining balance. |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 9 Months Ended |
Sep. 30, 2022 | |
Subsequent Events [Abstract] | |
SUBSEQUENT EVENTS | SUBSEQUENT EVENTS MLB Promotion Rights Agreement On October 11, 2022, Charlotte’s Web Holdings, Inc. (the “Company”) entered into a Promotional Rights Agreement (the “MLB Promotional Rights Agreement”) with MLB Advanced Media L.P., on its own behalf and on behalf of Major League Baseball Properties, Inc., the Office of the Commissioner of Baseball, The MLB Network, LLC and the Major League Baseball Clubs (collectively, the “MLB”), pursuant to which the Company entered into an exclusive strategic partnership with MLB to promote the Company’s new NSF-Certified for Sport® product line. In consideration for the MLB Promotional Rights Agreement, which expires on December 31, 2025, the Company shall pay the MLB over the term of the MLB Promotional Rights Agreement, an aggregate rights fee of $30.5 million and a 10% royalty on the Company’s gross revenue from the MLB branded products of the Company sold after sales of all such branded products exceed $18.0 million. The Company has also entered into a subscription agreement (the “Subscription Agreement”) pursuant to which the Company agreed to issue to the MLB, subject to customary closing conditions, common shares equal to 4% of the Company’s fully diluted outstanding common shares as of the day prior to the date of issue. The total number of shares issued to the MLB was 6,119,121 common shares of the Company, which were issued pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 of Regulation D promulgated under the Securities Act. The Company did not receive any proceeds in respect of the shares. Tilray Agreement On November 1, 2022, the Company entered into a Manufacturing and Sales License Agreement (the “Agreement”) with Aphria, Inc., an Ontario corporation, an affiliate of Tilray Brands, Inc. (“Tilray”), pursuant to which the parties entered into a strategic alliance by which Tilray will have the rights to licensing, manufacturing, quality, marketing and distribution of extract products in Canada. In consideration for the Agreement, Tilray has agreed to spend in each calendar year during the term of the Agreement (other than 2022) a minimum of 5% of net sales per year on advertising, retail marketing, direct to consumer advertising, and similar third-party marketing expenditures for the Company’s products. In addition, Tilray will spend an additional C$250 (Canadian Dollars) on marketing in the first contract year following 2022 to launch the Company’s brand into the Canadian market. Tilray will also pay the Company a monthly royalty of 10% of all net sales revenue received by Tilray from sales to third-party entities during the prior month. The Agreement expires on October 31, 2026, unless earlier terminated by either party in accordance with the terms of the Agreement. The Agreement is also subject to termination for convenience by either party upon 6 months’ notice given on or after October 31, 2024. BAT Subscription Agreement Effective as of November 14, 2022, the Company entered into a subscription agreement (the “Subscription Agreement”) with BT DE Investments, Inc. a wholly-owned subsidiary of BAT Group (LSE: BATS and NYSE: BTI), providing for the issuance of an approximately $56.8 million (C$75.3 million) convertible debenture (the “Debenture”) convertible into 19.9% ownership of the Company’s common shares at a conversion price of C$2.00 per common share of the Company on the Toronto Stock Exchange (TSX). The Debenture will accrue interest at an annualized rate of 5% until such time that there is federal regulation permitting the use of cannabidiol, a phytocannabinoid derived from the plant Cannabis sativa L. (“CBD”) as an ingredient in food products and dietary supplements in the United States. (The term “federal regulation" is defined as the date that federal laws in the United States permit, authorize or do not prohibit the use of CBD as an ingredient in food products and dietary supplements). Following federal regulation of CBD, the annualized rate of interest shall reduce to 1.5%. The maturity date for the Debenture shall be November 2029. The Subscription Agreement contains customary representations and warranties and covenants. The funds from this Debenture can be used for operating purposes to fund the Company, as approved by the board of directors or in accordance with the Company’s board-approved budget. |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES (Policies) | 9 Months Ended |
Sep. 30, 2022 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s financial position as of September 30, 2022 and its results of operations for the three and nine months ended September 30, 2022 and 2021, cash flows for the nine months ended September 30, 2022 and 2021, and stockholders’ equity for the three and nine months ended September 30, 2022 and 2021. Operating results for the three and nine months ended September 30, 2022, are not necessarily indicative of the results that may be expected for the full year ending December 31, 2022. The unaudited interim condensed consolidated financial statements presented herein do not contain the required disclosures under GAAP for annual consolidated financial statements. Certain amounts presented in prior periods have been reclassified to conform with the current period presentation. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 24, 2022. |
Inventories | Inventories Inventories are stated at the lower of cost or net realizable value. The Company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. The Company's inventory production process for cannabinoid products includes the cultivation of botanical raw material. Because of the duration of the cultivation process, a portion of the inventory will not be sold within one year. Consistent with the practice in other industries that cultivate botanical raw materials, all inventory is classified as a current asset. |
Revenue Recognition | Revenue RecognitionThe majority of the Company’s revenue is derived from sales of branded products to consumers via the Company's direct-to-consumer e-commerce website, and distributors, retail and wholesale business-to-business customers. |
Recently Adopted and Recently Issued Accounting Pronouncements | Recently Adopted Accounting Pronouncements Other than described below, no new accounting pronouncements adopted or issued by the FASB had or may have a material impact on the Company’s condensed consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which aims to reduce complexity in accounting standards by improving certain areas of U.S. GAAP without compromising information provided to users of financial statements. ASU 2019-12 is effective for public entities for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. For all other entities, the standard is effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted. There was an immaterial impact upon adoption on the condensed consolidated financial statements. In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance , which addresses that Current GAAP has no specific authoritative guidance on the accounting for, or the disclosure of, government assistance received by business entities. The pronouncement and subsequent amendments require the following annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy: 1) Information about the nature of the transactions and the related accounting policy used to account for the transactions; 2) The line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item, 3) Significant terms and conditions of the transactions, including commitments and contingencies. ASU 2021-10 is effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The Company evaluated the impact of the pronouncement, see further discussion within the Notes to Condensed Consolidated Financial Statements section "Income and Other Taxes". Recently Issued Accounting Pronouncements In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2020-04, Reference Rate Reform (Topic 848)—Facilitation of the Effects of Reference Rate Reform on Financial Reporting . This standard provides optional guidance for a limited time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments in this standard apply only to contracts and hedging relationships that reference LIBOR or another reference rate expected to be discontinued due to reference rate reform. The expedients and exceptions provided by the amendments do not apply to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022. The Company is currently evaluating the impact, if any, that the updated standard will have on the condensed consolidated financial statements. In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40):Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for convertible instruments by removing the separation 8 models for convertible debt instruments and convertible preferred stock with (1) cash conversion features, and (2) beneficial conversion features. In addition, ASU 2020-06 enhances information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 is effective for emerging growth companies for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company will evaluate the impact of the pronouncement and determined if there is any impact to the condensed consolidated financial statements if preferred shares are issued in future periods. |
SUMMARY OF SIGNIFICANT ACCOUN_3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Accounting Policies [Abstract] | |
Disaggregation of revenue | The following table sets forth the disaggregation of the Company’s revenue: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Direct-to-consumer $ 11,759 $ 15,175 $ 38,174 $ 46,988 Business-to-business 5,278 8,529 17,097 24,275 Total $ 17,037 $ 23,704 $ 55,271 $ 71,263 |
FAIR VALUE MEASUREMENT (Tables)
FAIR VALUE MEASUREMENT (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Fair Value Disclosures [Abstract] | |
Financial instruments measured at fair value on a recurring basis | The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis at September 30, 2022 and December 31, 2021, by level within the fair value hierarchy: September 30, 2022 Level 1 Level 2 Level 3 Total Financial assets: Stanley Brothers USA Purchase Option $ — $ — $ 9,100 $ 9,100 December 31, 2021 Level 1 Level 2 Level 3 Total Financial assets: Stanley Brothers USA Purchase Option $ — $ — $ 13,000 $ 13,000 |
Measurement inputs | The following additional assumptions are used in the model of the SBH Purchase Option: September 30, December 31, 2022 2021 Expected volatility 87.5% 92.5% Expected term (years) 2.9 3.7 Risk-free interest rate 4.2% 1.1% Weighted average cost of capital 45.0% 40% |
INVENTORIES (Tables)
INVENTORIES (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Inventory Disclosure [Abstract] | |
Inventories | Inventories consist of the following: September 30, December 31, 2022 2021 Harvested hemp and seeds $ 37,444 $ 38,249 Raw materials 12,617 15,189 Finished goods 14,865 13,974 64,926 67,412 Less: inventory provision (14,327) (15,335) Total inventory $ 50,599 $ 52,077 |
LEASES (Tables)
LEASES (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Leases [Abstract] | |
Maturities of operating lease liabilities | Maturities of operating lease liabilities as of September 30, 2022 are as follows: Operating Leases Year Ending December 31: 2022 (3 months remaining) $ 867 2023 3,415 2024 3,205 2025 2,896 2026 2,172 Thereafter 15,595 Total lease obligation 28,150 Less: Imputed interest (7,327) Total lease liabilities 20,823 Less: Current lease liabilities 2,316 Total non-current lease liabilities $ 18,507 |
CULTIVATION LIABILITIES (Tables
CULTIVATION LIABILITIES (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Cultivation Liabilities [Abstract] | |
Future payments due under contract obligations and scheduled maturities | Future payments due under cultivation contract obligations are as follows: Short-term Long-term Total December 31, 2021 $ 3,448 $ 385 $ 3,833 Crop costs incurred 169 — 169 Payments (2,640) — (2,640) Settlement reductions (582) — (582) Interest 32 — 32 Conversion to short-term borrowings 385 (385) — September 30, 2022 $ 812 $ — $ 812 |
SHAREHOLDERS_ EQUITY (Tables)
SHAREHOLDERS’ EQUITY (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Equity [Abstract] | |
Summary of number of warrants outstanding | The following summarizes the number of warrants outstanding as of September 30, 2022: Number of Warrants Weighted-Average Exercise Price per Warrant Outstanding as of December 31, 2021 6,983,140 $ 7.86 Granted — — Exercised — — Expired (6,983,140) $ 7.86 Outstanding as of September 30, 2022 — — |
LOSS PER SHARE (Tables)
LOSS PER SHARE (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Earnings Per Share [Abstract] | |
Computation of basic and diluted net loss per share | The following table sets forth the computation of basic and dilutive net loss per share attributable to common shareholders: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Net loss $ (7,588) $ (777) $ (24,084) $ (19,474) Weighted-average number of common shares - basic 145,334,992 120,270,444 145,203,515 112,688,338 Dilutive effect of stock options and awards — — — — Weighted-average number of proportionate voting shares - basic — 50,627 — 68,416 Weighted-average number of common shares - diluted 145,334,992 120,270,444 145,203,515 112,688,338 Weighted-average number of proportionate voting shares - diluted — 50,627 — 68,416 Loss per common share – basic and diluted $ (0.05) $ (0.01) $ (0.17) $ (0.14) Loss per proportionate voting share – basic and diluted $ — $ (2.21) $ — $ (55.62) |
Potentially dilutive awards | The potentially dilutive awards outstanding for each year are presented in the table below: September 30, 2022 2021 Outstanding options 4,625,261 3,881,721 Outstanding restricted share units 2,843,470 872,311 Outstanding common share warrants — 9,483,140 Total 7,468,731 14,237,172 |
SHARE-BASED COMPENSATION (Table
SHARE-BASED COMPENSATION (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Share-Based Payment Arrangement [Abstract] | |
Inputs used in valuation of awards | The following principal inputs were used in the valuation of awards issued for the nine months ended September 30, 2022 and 2021: Nine Months Ended September 30, 2022 2021 Expected volatility 85.8% 82.5% Expected term (years) 6.0 6.0 Risk-free interest rate 3.3% 1.3% Expected dividend yield 0% 0% Value of underlying share $0.43 $2.18 |
Detail of the number of stock options outstanding | Detail of the number of stock options outstanding for the three months ended September 30, 2022 under the Company's 2015 legacy option plan and the Company's amended 2018 long term incentive plan (collectively, the "Plans") is as follows: Number of Options Weighted- per Option Weighted- (in years) Aggregate Outstanding as of December 31, 2021 3,343,883 $ 3.16 7.54 $ 1,039,229 Granted 3,813,579 1.11 Exercised — — Forfeited (and expired) (2,532,201) 3.32 Outstanding as of September 30, 2022 4,625,261 $ 1.41 8.78 $ 170,184 Exercisable/vested as of September 30, 2022 1,579,296 $ 1.59 6.16 $ 14,184 |
Details of the number of restricted share awards outstanding | Details of the number of restricted share units outstanding under the 2018 Plan is as follows: Number of Shares Weighted- Outstanding as of December 31, 2021 1,816,851 $ 2.28 Granted 3,380,777 $ 0.91 Forfeited (1,748,387) $ 1.85 Vested (440,863) $ 2.00 Shares withheld upon vesting (164,908) $ 1.58 Outstanding as of September 30, 2022 2,843,470 $ 0.99 |
SUMMARY OF SIGNIFICANT ACCOUN_4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES - Disaggregation of Revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Disaggregation of Revenue [Line Items] | ||||
Revenue | $ 17,037 | $ 23,704 | $ 55,271 | $ 71,263 |
Direct-to-consumer | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue | 11,759 | 15,175 | 38,174 | 46,988 |
Business-to-business | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue | $ 5,278 | $ 8,529 | $ 17,097 | $ 24,275 |
FAIR VALUE MEASUREMENT - Financ
FAIR VALUE MEASUREMENT - Financial Instruments Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Financial assets: | ||
Stanley Brothers USA Holdings purchase option | $ 9,100 | $ 13,000 |
Level 1 | ||
Financial assets: | ||
Stanley Brothers USA Holdings purchase option | 0 | 0 |
Level 2 | ||
Financial assets: | ||
Stanley Brothers USA Holdings purchase option | 0 | 0 |
Level 3 | ||
Financial assets: | ||
Stanley Brothers USA Holdings purchase option | $ 9,100 | $ 13,000 |
FAIR VALUE MEASUREMENT - Fair V
FAIR VALUE MEASUREMENT - Fair Value Measurement Inputs - Purchase Option (Details) (Details) | Sep. 30, 2022 year | Dec. 31, 2021 year |
Expected volatility | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Purchase option, measurement input | 0.875 | 0.925 |
Expected term (years) | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Purchase option, measurement input | 2.9 | 3.7 |
Risk-free interest rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Purchase option, measurement input | 0.042 | 0.011 |
Weighted average cost of capital | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Purchase option, measurement input | 0.450 | 0.40 |
FAIR VALUE MEASUREMENT - Narrat
FAIR VALUE MEASUREMENT - Narrative (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||||||
Jun. 18, 2022 | May 08, 2022 | Mar. 02, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Fair Value, Option, Quantitative Disclosures [Line Items] | ||||||||
Gain (loss) on change in fair value of purchase option | $ (4,000) | $ 5,730 | $ (3,900) | $ 4,900 | ||||
Assets | 140,518 | $ 140,518 | $ 171,513 | |||||
Warrants expired (in shares) | 5,750,000 | 1,233,140 | 6,983,140 | |||||
Gain related to warrant liabilities | 0 | $ 2,638 | $ 0 | 4,081 | ||||
Stanley Brothers USA Holdings purchase option | $ 9,100 | 9,100 | $ 13,000 | |||||
Purchase option | $ 8,000 | $ 0 | $ 8,000 | |||||
Business combination purchase option, term | 5 years | |||||||
Business combination purchase option, extension term | 2 years | |||||||
Class of warrant or right, percentage of outstanding shares | 10% | |||||||
Warrants expiration period | 60 days |
INVENTORIES (Details)
INVENTORIES (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Inventory Disclosure [Abstract] | ||
Harvested hemp and seeds | $ 37,444 | $ 38,249 |
Raw materials | 12,617 | 15,189 |
Finished goods | 14,865 | 13,974 |
Inventory, gross | 64,926 | 67,412 |
Less: inventory provision | (14,327) | (15,335) |
Inventories, net | $ 50,599 | $ 52,077 |
DEBT (Details)
DEBT (Details) | Jul. 27, 2022 USD ($) |
Line of Credit Facility [Line Items] | |
Maximum borrowing capacity | $ 10,000,000 |
Prime rate | |
Line of Credit Facility [Line Items] | |
Basis spread on variable interest rate | 1% |
LIBOR | |
Line of Credit Facility [Line Items] | |
Basis spread on variable interest rate | 2.50% |
LEASES - Narrative (Details)
LEASES - Narrative (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Lessee, Lease, Description [Line Items] | ||||
Renewal term | 5 years | 5 years | ||
Asset impairment | $ 1,822 | $ 0 | $ 1,822 | $ 0 |
Maximum | ||||
Lessee, Lease, Description [Line Items] | ||||
Remaining lease terms | 12 years | 12 years |
LEASES - Maturities of Operatin
LEASES - Maturities of Operating Lease Liabilities (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Year Ending December 31: | ||
2022 (3 months remaining) | $ 867 | |
2023 | 3,415 | |
2024 | 3,205 | |
2025 | 2,896 | |
2026 | 2,172 | |
Thereafter | 15,595 | |
Total lease obligation | 28,150 | |
Less: Imputed interest | (7,327) | |
Total lease liabilities | 20,823 | |
Less: Current lease liabilities | 2,316 | $ 2,103 |
Total non-current lease liabilities | $ 18,507 | $ 20,500 |
CULTIVATION LIABILITIES - Contr
CULTIVATION LIABILITIES - Contract Obligations (Details) $ in Thousands | 9 Months Ended |
Sep. 30, 2022 USD ($) | |
Cultivation Liabilities [Abstract] | |
Short-term, beginning | $ 3,448 |
Short-term, costs incurred | 169 |
Short-term, payments | (2,640) |
Short-term, settlement reductions | (582) |
Short-term, interest | 32 |
Short-term, conversion to short-term borrowings | 385 |
Short-term, ending | 812 |
Long-term, beginning | 385 |
Long-term, costs incurred related to 2021 crop | 0 |
Long-term, payments | 0 |
Long-term, settlement reductions | 0 |
Long-term, interest | 0 |
Long-term, conversion to short-term borrowings | (385) |
Long-term, ending | 0 |
Total, beginning | 3,833 |
Total, costs incurred related to 2021 crop | 169 |
Total, payments | (2,640) |
Total, settlement reductions | (582) |
Total, interest | 32 |
Total, conversion to short-term borrowings | 0 |
Total, ending | $ 812 |
SHAREHOLDERS_ EQUITY - Narrativ
SHAREHOLDERS’ EQUITY - Narrative (Details) - $ / shares | 9 Months Ended | ||||
Jun. 18, 2022 | May 08, 2022 | Sep. 30, 2022 | Dec. 31, 2021 | Nov. 03, 2021 | |
Equity [Abstract] | |||||
Common shares, issued (in shares) | 145,509,372 | 144,659,964 | 142,335,464 | ||
Common shares, outstanding (in shares) | 145,509,372 | 144,659,964 | 142,335,464 | ||
PVS, issued (in shares) | 0 | 0 | 0 | ||
PVS, outstanding (in shares) | 0 | 0 | 0 | ||
Preferred shares, issued (in shares) | 0 | ||||
Preferred shares, outstanding (in shares) | 0 | ||||
Warrants expired (in shares) | 5,750,000 | 1,233,140 | 6,983,140 | ||
Warrants expired, weighted average exercise price (in usd per share) | $ 6.27 | $ 15.29 | $ 7.86 |
SHAREHOLDERS_ EQUITY - Warrants
SHAREHOLDERS’ EQUITY - Warrants Outstanding (Details) - $ / shares | 9 Months Ended | ||
Jun. 18, 2022 | May 08, 2022 | Sep. 30, 2022 | |
Number of Warrants | |||
Outstanding (in shares) | 6,983,140 | ||
Granted (in shares) | 0 | ||
Exercised (in shares) | 0 | ||
Expired (in shares) | (5,750,000) | (1,233,140) | (6,983,140) |
Outstanding (in shares) | 0 | ||
Weighted-Average Exercise Price per Warrant | |||
Outstanding (in usd per share) | $ 7.86 | ||
Granted (in usd per share) | 0 | ||
Exercised (in usd per share) | 0 | ||
Expired (in usd per share) | $ 6.27 | $ 15.29 | 7.86 |
Outstanding (in usd per share) | $ 0 |
LOSS PER SHARE - Narrative (Det
LOSS PER SHARE - Narrative (Details) | 9 Months Ended | |||
Nov. 14, 2022 shares | Oct. 12, 2022 shares | Oct. 11, 2022 shares | Sep. 30, 2022 | |
Subsequent Event [Line Items] | ||||
PVS, conversion ratio | 400 | |||
BAT Subscription Agreement | Subsequent Event | ||||
Subsequent Event [Line Items] | ||||
Conversion to common shares (in shares) | 37,670,540 | |||
MLB | Subsequent Event | Private Placement | ||||
Subsequent Event [Line Items] | ||||
Share offering, shares/units issued (in shares) | 6,119,121 | 6,119,121 |
LOSS PER SHARE - Basic and Dilu
LOSS PER SHARE - Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | ||||||
Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Earnings Per Share [Abstract] | ||||||||
Net loss | $ (7,588) | $ (7,870) | $ (8,626) | $ (777) | $ (5,923) | $ (12,774) | $ (24,084) | $ (19,474) |
Weighted-average number of common shares - basic (in shares) | 145,334,992 | 140,521,244 | 145,203,515 | 140,054,738 | ||||
Weighted-average number of common shares - basic (in shares) | 120,270,444 | 112,688,338 | ||||||
Dilutive effect of stock options and awards (in shares) | 0 | 0 | 0 | 0 | ||||
Weighted-average number of proportionate voting shares - basic | 0 | 50,627 | 0 | 68,416 | ||||
Weighted-average number of common shares - diluted (in shares) | 145,334,992 | 140,521,244 | 145,203,515 | 140,054,738 | ||||
Weighted-average number of common shares - diluted (in shares) | 120,270,444 | 112,688,338 | ||||||
Weighted-average number of proportionate voting shares - diluted | 0 | 50,627 | 0 | 68,416 | ||||
Loss per common share - basic (in usd per share) | $ (0.05) | $ (0.01) | $ (0.17) | $ (0.14) | ||||
Loss per common share - diluted (in usd per share) | (0.05) | (0.01) | (0.17) | (0.14) | ||||
Loss per proportionate voting share - basic (in usd per share) | 0 | (2.21) | 0 | (55.62) | ||||
Loss per proportionate voting share - diluted (in usd per share) | $ 0 | $ (2.21) | $ 0 | $ (55.62) |
LOSS PER SHARE - Potentially Di
LOSS PER SHARE - Potentially Dilutive Awards (Details) - shares | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Potentially dilutive awards (in shares) | 7,468,731 | 14,237,172 |
Outstanding options | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Potentially dilutive awards (in shares) | 4,625,261 | 3,881,721 |
Outstanding restricted share units | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Potentially dilutive awards (in shares) | 2,843,470 | 872,311 |
Outstanding common share warrants | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Potentially dilutive awards (in shares) | 0 | 9,483,140 |
SHARE-BASED COMPENSATION - Narr
SHARE-BASED COMPENSATION - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Options granted, weighted average grant-date fair value (in usd per share) | $ 1.11 | $ 4.63 | ||
Options exercised, weighted average share price (in usd per share) | $ 0 | $ 3.64 | ||
Fair value of shares vested | $ 881 | $ 354 | ||
Share-based compensation expense | $ 664 | $ 1,579 | 2,686 | $ 4,128 |
Unrecognized share based compensation expense | $ 6,114 | $ 6,114 | ||
Unrecognized share based compensation expense, period for recognition | 2 years 6 months | |||
Options | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Prescribed service period | 4 years | |||
Restricted share units | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Vesting period | 4 years |
SHARE-BASED COMPENSATION - Fair
SHARE-BASED COMPENSATION - Fair Value Inputs (Details) - $ / shares | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | |
Share-Based Payment Arrangement [Abstract] | ||
Expected volatility | 85.80% | 82.50% |
Expected term | 6 years | 6 years |
Risk-free interest rate | 3.30% | 1.30% |
Expected dividend yield | 0% | 0% |
Value of underlying share (in usd per share) | $ 0.43 | $ 2.18 |
SHARE-BASED COMPENSATION - Opti
SHARE-BASED COMPENSATION - Options Outstanding (Details) - USD ($) | 9 Months Ended | 12 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] | |||
Outstanding (in shares) | 3,343,883 | ||
Granted (in shares) | 3,813,579 | ||
Exercised (in shares) | 0 | ||
Forfeited (and expired) (in shares) | (2,532,201) | ||
Outstanding (in shares) | 4,625,261 | 3,343,883 | |
Exercisable/vested (in shares) | 1,579,296 | ||
Weighted-Average Exercise Price Per Option | |||
Outstanding (in usd per share) | $ 1.41 | $ 3.16 | |
Granted (in usd per share) | 1.11 | $ 4.63 | |
Exercised (in usd per share) | 0 | ||
Forfeited (and expired) (in usd per share) | 3.32 | ||
Outstanding (in usd per share) | 1.41 | $ 3.16 | |
Exercisable/vested (in usd per share) | $ 1.59 | ||
Weighted-Average Remaining Contract Term | |||
Outstanding | 8 years 9 months 10 days | 7 years 6 months 14 days | |
Exercisable/vested | 6 years 1 month 28 days | ||
Aggregate Intrinsic Value | |||
Outstanding | $ 170,184 | $ 1,039,229 | |
Exercisable/vested | $ 14,184 |
SHARE-BASED COMPENSATION - Rest
SHARE-BASED COMPENSATION - Restricted Share Units Outstanding (Details) | 9 Months Ended |
Sep. 30, 2022 $ / shares shares | |
Number of Shares | |
Outstanding (in shares) | shares | 1,816,851 |
Granted (in shares) | shares | 3,380,777 |
Forfeited (in shares) | shares | (1,748,387) |
Vested (in shares) | shares | (440,863) |
Shares withheld upon vesting (in shares) | shares | (164,908) |
Outstanding (in shares) | shares | 2,843,470 |
Weighted-Average Grant Date Fair Value | |
Outstanding (in usd per share) | $ / shares | $ 2.28 |
Granted (in usd per share) | $ / shares | 0.91 |
Forfeited (in usd per share) | $ / shares | 1.85 |
Vested (in usd per share) | $ / shares | 2 |
Shares withheld upon vesting (in usd per share) | $ / shares | 1.58 |
Outstanding (in usd per share) | $ / shares | $ 0.99 |
INCOME AND OTHER TAXES (Details
INCOME AND OTHER TAXES (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2022 | Sep. 30, 2021 | |
Income Tax Disclosure [Abstract] | |||
Effective tax rate | 0% | 0% | |
Income tax refund received | $ 10,841 | ||
Effective income tax rate reconciliation, tax credit, amount | $ 4,106 |
RELATED PARTY TRANSACTIONS (Det
RELATED PARTY TRANSACTIONS (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||||||
Apr. 16, 2021 | Mar. 02, 2021 | Nov. 30, 2020 | Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Related Party Transaction [Line Items] | ||||||||
Note receivable from related party | $ 1,000,000 | $ 1,037 | $ 1,037 | $ 1,037 | ||||
Note receivable interest rate | 3.25% | |||||||
Purchase option | $ 8,000 | 0 | $ 8,000 | |||||
Related party manufacturing agreement | ||||||||
Related Party Transaction [Line Items] | ||||||||
Related party expenses | 1,254 | $ 947 | $ 2,943 | 3,133 | ||||
Payment terms | 30 days | |||||||
Related party liability | 258 | $ 258 | $ 119 | |||||
Related party consulting services | ||||||||
Related Party Transaction [Line Items] | ||||||||
Related party expenses | 150 | $ 167 | 1,025 | $ 167 | ||||
Consulting agreement, extended term | 1 year | |||||||
Payments to related party | $ 2,081 | |||||||
Prepaid expense, current | $ 0 | $ 0 |
SUBSEQUENT EVENTS (Details)
SUBSEQUENT EVENTS (Details) - Subsequent Event $ / shares in Units, $ in Thousands, $ in Thousands | Nov. 14, 2022 USD ($) | Nov. 14, 2022 CAD ($) $ / shares | Oct. 12, 2022 shares | Oct. 11, 2022 USD ($) shares | Nov. 01, 2022 CAD ($) |
BAT Subscription Agreement | Convertible Debt | |||||
Subsequent Event [Line Items] | |||||
Proceeds from convertible debt | $ 56,800 | $ 75,300 | |||
Debt instrument, convertible, percentage of ownership | 19.90% | ||||
Debt instrument, convertible, conversion price | $ / shares | $ 2 | ||||
Debt instrument, interest rate, stated percentage | 5% | ||||
Debenture, interest rate | 1.50% | ||||
MLB | Private Placement | |||||
Subsequent Event [Line Items] | |||||
Sale of stock, percentage of ownership after transaction | 4% | ||||
Share offering, shares/units issued (in shares) | shares | 6,119,121 | 6,119,121 | |||
MLB | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | |||||
Subsequent Event [Line Items] | |||||
Aggregate rights fee | $ 30,500 | ||||
Royalty percentage of gross revenue | 10% | ||||
Collaborative arrangement, rights and obligations, royalty maximum revenue | $ 18,000 | ||||
Tilray | License | |||||
Subsequent Event [Line Items] | |||||
Revenue, remaining performance obligation, percentage of net sales | 5% | ||||
Revenue, remaining performance obligation, amount | $ 250 | ||||
Revenue, remaining performance obligation, percentage | 10% |